Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty

Treatment of Exercise-Induced Pulmonary Vascular Dysfunction in Symptomatic Patients After Pulmonary Thromboendarterectomy

This is an open label study of Riociguat in patients with continued exercise intolerance at least 6 months following pulmonary endarterectomy (PEA).

Inclusion Criteria:

• Adult patients who underwent PTE or BPA for Chronic thromboembolic pulmonary hypertension (CTEPH) at least six months prior to screening and report ongoing subjective exercise limitation,
• able to give consent
• able to perform a exercise protocol

Exclusion Criteria:

• Patients with known Residual Pulmonary Hypertension (RPH) by RHC following PTE for CTEPH
• ongoing PAH-specific vasodilator therapy
• known contraindication to riociguat
• a physical limitation to completing an exercise protocol